A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs GSK-3858279 (Primary) ; GSK-3858279 (Primary)
- Indications Pain
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 24 Sep 2019 Planned End Date changed from 27 Nov 2019 to 22 Feb 2021.
- 24 Sep 2019 Planned primary completion date changed from 27 Nov 2019 to 22 Feb 2021.
- 31 Aug 2018 Biomarkers information updated